logo
Plus   Neg
Share
Email

Roche: FDA Approves Actemra/RoActemra For Systemic Sclerosis-associated Interstitial Lung Disease

Roche (RHHBY) said FDA has approved Actemra/RoActemra subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease. Actemra/RoActemra is the first biologic therapy approved for the treatment of the disease. The FDA approval is based on data from the focuSSced trial, a phase III randomised, double-blind, placebo-controlled clinical trial.

The company noted that this is the sixth FDA approved indication for Actemra/RoActemra since the medicine was launched in the U.S. in 2010.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.
Follow RTT